{"entity":{"id":"nct07006077","kind":"trial","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Recombinant human IL-21-expressing oncolytic vaccinia virus injection in pancreatic ductal adenocarcinoma, run by Hangzhou Converd Co., Ltd., now recruiting.","summary":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT07006077 by Hangzhou Converd Co., Ltd., with 12 participants planned, started 2025-05-29 and due to reach its primary completion in 2028-12-31. Interventions recorded: Recombinant human IL-21-expressing oncolytic vaccinia virus injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07006077","url":"https://clinicaltrials.gov/study/NCT07006077"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07006077","phase":"2","setting":"A Phase II Trial to Evaluate the Efficacy of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Pancreatic Tumors","sponsor":"Hangzhou Converd Co., Ltd.","enrolled":12,"outcomes":[]},"route":"/trials/nct07006077/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}